Country: Canada
Language: English
Source: Health Canada
GANCICLOVIR (GANCICLOVIR SODIUM)
STERIMAX INC
J05AB06
GANCICLOVIR
500MG
POWDER FOR SOLUTION
GANCICLOVIR (GANCICLOVIR SODIUM) 500MG
INTRAVENOUS
25 VIALS
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0128037002; AHFS:
APPROVED
2018-05-04
PRODUCT MONOGRAPH Pr GANCICLOVIR FOR INJECTION USP 500 mg/vial ganciclovir (as ganciclovir sodium) USP Sterile Powder for Solution Antiviral Agent SteriMax Inc. Date of Preparation: 2770 Portland Drive May 3, 2018 Oakville, ON L6H 6R4 Submission Control No: 201580 _Ganciclovir for Injection USP _ _Page 2 of 60_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ...................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................ 3 CONTRAINDICATIONS ................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................ 4 ADVERSE REACTIONS ............................................................................................... 11 DRUG INTERACTIONS ................................................................................................ 23 DOSAGE AND ADMINISTRATION ... ………………………………………………27 OVERDOSAGE .............................................................................................................. 31 ACTION AND CLINICAL PHARMACOLOGY .. ………………………………...…32 STORAGE AND STABILITY ........................................................................................ 33 SPECIAL HANDLING INSTRUCTIONS ..................................................................... 33 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................... 34 PART II: SCIENTIFIC INFORMATION .............................................................................. 35 PHARMACEUTICAL INFORMATION ....................................................................... 35 CLINICAL TRIALS ........................................................................................................ 36 DETAILED PHA Read the complete document